Avenue Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Avenue Therapeutics kazanç ve gelirinin sırasıyla yıllık 18.7% ve 100.3% oranında artması tahmin edilirken, EPS'nin yıllık 53% oranında büyümesi bekleniyor.

Anahtar bilgiler

18.7%

Kazanç büyüme oranı

53.0%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	21.6%
Gelir büyüme oranı	100.3%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:49Y - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	N/A	-17	N/A	N/A	1
12/31/2025	N/A	-14	N/A	N/A	1
12/31/2024	N/A	-12	N/A	N/A	1
9/30/2024	N/A	-9	-11	-11	N/A
6/30/2024	N/A	-15	-10	-9	N/A
3/31/2024	N/A	-11	-14	-11	N/A
12/31/2023	N/A	-10	-12	-9	N/A
9/30/2023	N/A	-10	-14	-11	N/A
6/30/2023	N/A	-12	-13	-11	N/A
3/31/2023	N/A	-8	-7	-7	N/A
12/31/2022	N/A	-4	-8	-8	N/A
9/30/2022	N/A	-5	-5	-5	N/A
6/30/2022	N/A	-5	-5	-5	N/A
3/31/2022	N/A	-6	-4	-4	N/A
12/31/2021	N/A	-4	-4	-4	N/A
9/30/2021	N/A	-4	-4	-4	N/A
6/30/2021	N/A	-4	-4	-4	N/A
3/31/2021	N/A	-5	-5	-5	N/A
12/31/2020	N/A	-5	-5	-5	N/A
9/30/2020	N/A	-10	-8	-8	N/A
6/30/2020	N/A	-11	-9	-9	N/A
3/31/2020	N/A	-16	-22	-22	N/A
12/31/2019	N/A	-26	-26	-26	N/A
9/30/2019	N/A	-24	-23	-23	N/A
6/30/2019	N/A	-25	-25	-25	N/A
3/31/2019	N/A	-22	-17	-17	N/A
12/31/2018	N/A	-22	-18	-18	N/A
9/30/2018	N/A	-24	-21	-21	N/A
6/30/2018	N/A	-24	N/A	-19	N/A
3/31/2018	N/A	-22	N/A	-14	N/A
12/31/2017	N/A	-12	N/A	-7	N/A
9/30/2017	N/A	-7	N/A	-3	N/A
6/30/2017	N/A	-4	N/A	-1	N/A
3/31/2017	N/A	-3	N/A	-1	N/A
12/31/2016	N/A	-3	N/A	-2	N/A
9/30/2016	N/A	-4	N/A	-2	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 49Y önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 49Y önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 49Y önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 49Y gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: 49Y gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 49Y 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Avenue Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast breakeven pushed back to 2024

Forecast breakeven pushed back to 2024

Recent updates

New major risk - Financial position

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

New major risk - Revenue and earnings growth

Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy

Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

New major risk - Revenue and earnings growth

the Staff of Nasdaq Determines to Delist Avenue Therapeutics’ Securities from Nasdaq Based Upon its Continued Non-Compliance with the Rule

New major risk - Financial position

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Executive Director recently bought €234k worth of stock

Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol

Avenue Therapeutics Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Avenue Therapeutics, Inc. announced that it has received $0.24 million in funding

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. (NasdaqCM:ATXI) acquired Baergic Bio, Inc.

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $27.6 million.

Avenue Therapeutics, Inc. Submits Type A Meeting Request and Related Briefing Documents to the FDA

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Avenue Therapeutics, Inc. Announces Management Changes

Avenue Therapeutics Receives Non-Compliance Letter from Nasdaq

Avenue Therapeutics, Inc. Announces CEO Changes

Less than half of directors are independent

Avenue Therapeutics, Inc. Receives an Acknowledgement Letter from the Office of New Drugs of the Food and Drug Administration Regarding Avenue’s August 31, 2021 Formal Dispute Resolution Request

Avenue Therapeutics, Inc.(NasdaqCM:ATXI) dropped from Russell 3000E Index

Forecast breakeven pushed back to 2024

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Forecast breakeven pushed back to 2024

Avenue Therapeutics, Inc. Resubmits New Drug Application to the U.S. Food and Drug Administration for IV Tramadol

New 90-day high: €5.65

Avenue Therapeutics, Inc. Provides Regulatory Update for IV Tramadol

Avenue Therapeutics, Inc. Announces Thomas G. Moore to Resign from the Board of Directors of the Company, Effective December 31, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin